Wedbush Maintains Outperform on BridgeBio Oncology, Lowers Price Target to $9
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $25 to $9.
Wedbush analyst David Nierengarten maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and lowers the price target from $25 to $9.